Physician profile
Peter G Ford
NPI 1164451639
$4,338.99
in general payments reported to CMS, 2019-2025
30 companies · $740 in 2025
The $740 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $264 · 2021: $315 · 2022: $260 · 2023: $696 · 2024: $624 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.62 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.60 | 2019-2025 | |
| Janssen Biotech, INC. | $661.76 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $478.56 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $379.40 | 2019-2025 | |
| Ucb, INC. | $309.38 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $297.84 | 2019-2023 | |
| Genzyme Corporation | $269.38 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $125.84 | 2019-2025 | Winlevi |
| Amgen INC. | $110.88 | 2019-2023 | Otezla |
| Incyte Corporation | $90.15 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $85.53 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $82.65 | 2019-2025 | Dupixent |
| Epi Health, LLC | $70.55 | 2022 | |
| Celgene Corporation | $70.23 | 2019 | |
| Leo Pharma INC. | $67.67 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.14 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $37.86 | 2019-2020 | |
| Krystal Biotech INC | $31.86 | 2024 | Vyjuvek |
| Botanix Sb INC | $29.51 | 2025 | Sofdra |
| Csl Behring | $24.87 | 2019 | |
| Almirall LLC | $24.19 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.58 | 2024 | Ycanth |
| Mylan Pharmaceuticals INC. | $22.42 | 2019 | |
| Vyne Pharmaceuticals INC. | $21.75 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.48 | 2019 | |
| Genentech USA, INC. | $21.06 | 2019 | |
| Arcutis Biotherapeutics, INC. | $20.99 | 2024 | Zoryve |
| Dermavant Sciences, INC. | $20.48 | 2023 | Vtama |
| Mayne Pharma Commercial LLC | $16.92 | 2019 | |
| Galderma Laboratories, L.P. | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.